Navigation Links
National Eye Institute Launches Ancillary Study to AREDS2 With ForeseeHome(TM) AMD Monitor

ST. LOUIS, June 15 /PRNewswire/ -- The National Eye Institute, of the U.S. National Institutes of Health, announced the launch of an ancillary study to the ongoing Age-Related Eye Disease Study 2 (AREDS2).  AREDS2 is a nationwide study of 4,000 individuals at moderate to high risk for developing age-related macular degeneration (AMD) to determine whether oral supplementation of lutein/zeaxanthin and omega-3 fatty acids can further slow the progression of vision loss from AMD, the leading cause of vision loss in the United States for people over age 60.

The objective of this ancillary study is to determine if home monitoring using the ForeseeHome™ AMD Monitor would lead to earlier detection of wet AMD when compared with standard care, and result in better visual acuity following therapy at one year.

The ForeseeHome™ AMD Monitor is the first ophthalmic device designed to provide ongoing monitoring of patients with AMD between visits to their eye care professional.  Patients complete a brief exam on their ForeseeHome™ AMD Monitor in the comfort of their own home, and data are transmitted to the Notal Vision Data Monitoring Center.  The award winning ergonomic design of the ForeseeHome™ AMD Monitor is comfortable and easy to use for patients at risk of vision loss from AMD.

Notal Vision was founded by a team of medical professionals determined to develop better methods of AMD monitoring and reduce vision loss associated with AMD. For more information, please visit

The National Eye Institute (NEI) is part of the National Institutes of Health (NIH) and is the Federal government's lead agency for vision research that leads to sight-saving treatments and plays a key role in reducing visual impairment and blindness. For more information, visit the NEI Website at

The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

SOURCE Notal Vision
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chindex International, Inc. Reports Fourth Quarter and Full Year Fiscal 2010 Financial Results
2. Veteran International Health Care Executive Appointed CEO of BeneChill(R)
3. Abstract Submissions and Registration Now Open for 2nd International Symposium on MR-Guided Focused Ultrasound
4. AstraZeneca to Support Drug-Induced Liver Injury Network at the National Institutes of Health
5. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
6. Receives VIPPS Accreditation From The National Association of Boards of Pharmacy
7. National Anesthesia Services, Inc. Celebrates 21 Years of Dynamic Growth and Achievement
8. Systech International and Videojet Brazil Partner to Meet Brazils Emerging Pharmaceutical Regulatory Requirements
9. Drug Production in Afghanistan: A Challenge for the International Community
10. China Ruitai International Holdings Co., Ltd. Reports Results for the First Quarter 2010
11. OXIS International, Inc. Announces Its Attendance at the Rodman & Renshaw Annual Global Investment Conference in London, May 16-18, 2010
Post Your Comments:
(Date:11/27/2015)... -- --> --> ... potential to save costs, improve treatment quality and accelerate ... exploited as yet. Here, particular emphasis is placed on ... tablet or directly at the patients, bedside. ... -->      (Photo: ) ...
(Date:11/27/2015)... -- Research and Markets ( ) has announced ... 2015-2019" report to their offering. ... the author the present scenario and growth prospects of ... the market size, the report considers revenue generated from ... and copper IUDs. The report forecasts the global intrauterine ...
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in ... that delves into an array of issues that are presently affecting Americans. Dedicated to ... dialogue, this show is changing the subjects consumers focus on, one episode at a ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men ... prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown ... helped advance the healthcare industry as a whole through their advocacy and professional ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients ... central Michigan, have come together on Thanksgiving Day to share the things that ... viewing on the Serenity Point YouTube channel, patients displayed what they wrote on ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... workshops to discuss bioavailability and the need to integrate dose form selection in ... collaboration with OBN, the membership organization supporting and bringing together the UK’s emerging ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes ... titles work with any font, giving users limitless opportunities to stylize and create ...
Breaking Medicine News(10 mins):